Related Experiment Video

Updated: Jan 28, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

1.1K

Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights

Justin E Ideozu1,2,3, Xi Zhang4,5,6, Susanna McColley7,8

  • 1Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA. justin.ideozu@northwestern.edu.

Genes
|March 1, 2019
PubMed

Insights

Cystic Fibrosis (CF) research uses transcriptome profiling to understand disease variability and find new therapeutic targets. This approach aids in developing treatments beyond current gene therapies and small molecules for CFTR mutations.

Area of Science:

  • Biochemistry
  • Genetics
  • Molecular Biology

Background:

  • Cystic Fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to impaired ion transport and variable, system-wide consequences.
  • Current CF treatments, including gene replacement, gene editing, and small molecules, face limitations in efficacy, delivery, and applicability to diverse CFTR mutations.

Purpose of the Study:

  • To review insights from transcriptome profiling in CF studies.
  • To highlight recent advances in molecular therapeutics for CF.
  • To underscore the need for characterizing CF pathophysiology mechanisms.

Main Methods:

  • Transcriptome profiling to analyze gene expression patterns in CF.
  • Review of current gene replacement, gene editing, and small molecule therapeutic strategies.
  • Analysis of molecular targets for CF treatment.

Main Results:

  • Transcriptome profiling offers a robust method for characterizing phenotypic variability in CF.
  • This approach can reveal novel molecular targets with therapeutic potential.
  • Current therapeutic strategies have limitations in addressing the full spectrum of CF.

Conclusions:

  • Transcriptome profiling is crucial for understanding CF heterogeneity and identifying new therapeutic avenues.
  • Further research into molecular targets is needed to overcome limitations of existing CF treatments.
  • Integrating transcriptome data with therapeutic development can advance one-time CF treatments.
Keywords:
RNA-Seqcystic fibrosismicroarraymolecular therapytranscriptome profiling

More Related Videos

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.8K
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

480

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
868
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
520
Molecular Models02:00

Molecular Models

Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
43.7K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.7K
Overview of Advanced Functional Groups02:22

Overview of Advanced Functional Groups


Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
29.7K
Extraction: Advanced Methods00:56

Extraction: Advanced Methods

Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.1K